H1 sales growth for Novo Nordisk’s segment that includes Ozempic and Wegovy was down from the same period in 2024.

Novo Nordisk's already depressed share price has fallen again this morning, despite reporting an 18% increase in sales in the ...

Novo Nordisk just pulled Wegovy from a major telehealth platform over safety concerns about knockoff versions. Here's what ...

Novo Nordisk reported second quarter earnings a week after revising its 2025 outlook down on slower GLP-1 sales.

Danish pharmaceutical giant Novo Nordisk posted a sharp rise in second-quarter net profit Wednesday, but rising competition ...

Shares of Novo Nordisk, the Danish pharmaceutical giant behind Ozempic and Wegovy, fell in pre-market trading and on the ...

No revenue reported as Terns remains a clinical-stage, pre-commercial biotech. A strong cash position of $315.4 million as of Q2 2025 is expected to fund operations into 2028.

The outgoing chief executive of Novo Nordisk has revealed plans to ramp-up cost cutting 'efficiencies' across the business, ...

Novo Nordisk has abandoned another GLP-1/GIP co-agonist and CB1 receptor as part of a significant pipeline clearout that ...

Novo Nordisk, the maker of Wegovy, plans to cut costs and refocus commercially after a $95 billion stock loss. The company's market cap has dropped to around $212 billion.

Glencore Earnings Fall on Lower Coal Prices, Copper Production Challenges The commodities giant said the results reflect lower coal prices and a drop in copper production following operational ...